Never in history have health care systems had access to such an enormous armamentarium of diagnostic procedures, treatment options, and resources to prevent diseases and their spread, as well as to improve the health care of individual patients and the health of populations.
At the same time, health care providers find themselves faced with an ever-growing loss of autonomy – as, throughout the world, systems of health care delivery and financing are increasingly subject to resource constraints.
From the scarcity of resources available in social health care systems follows an ethical imperative that decision-makers choose wisely, consider the opportunity costs of these choices, and accept accountability for reasonableness of their actions. This is equally true for National Health Service (NHS) systems (“Beveridge-type”, as for example in the United Kingdom), insurance-based health systems (“Bismarck model”, as for example in Germany), and market- and managed care-driven health care systems (as for example in the United States).
At InnoValHC, we are committed to support health care resource allocation decisions by robust analysis. This includes decision analytic and economic modeling as well as strategic advice spanning process development, project management, product valuation, portfolio optimization and strategic R&D management (see Our Offers).
We believe that the decision problem and the research questions at hand should dictate the optimal approach to problem-solving, not the other way around. As real-world decision-makers are acutely aware of, academic research – not excluding the field of health economics – does not always meet this requirement.